<DOC>
	<DOCNO>NCT01573468</DOCNO>
	<brief_summary>This study perform evaluate efficacy safety capecitabine combination tesetaxel versus capecitabine combination placebo second-line treatment patient gastric cancer .</brief_summary>
	<brief_title>Capecitabine/Tesetaxel Versus Capecitabine/Placebo Second-line Therapy Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Key inclusion criterion : 1 . Histologically cytologically confirm gastric adenocarcinoma , include gastric gastroesophagealjunction adenocarcinoma ( Histologically confirm adenocarcinoma low esophagus acceptable radiographic endoscopic documentation gastroesophagealjunction proximalstomach involvement . ) 2 . Measurable disease ( revised RECIST ) base compute tomography , nonmeasurable disease 3 . ECOG performance status 0 1 4 . Treatment 1 prior regimen ( firstline therapy ) must include fluoropyrimidine platinumcontaining agent ( Prior adjuvant neoadjuvant chemotherapy acceptable provide 6 month elapse end therapy start firstline therapy . ) 5 . Disease progression start 1 prior regimen base compute tomography 6 . Adequate bone marrow , hepatic , renal function 7 . Ability swallow oral soliddosage form medication Key exclusion criterion : 1 . Squamous cell gastric carcinoma 2 . Boneonly metastatic disease 3 . History presence brain metastasis leptomeningeal disease 4 . Operable gastric gastroesophagealjunction cancer 5 . HER2positive disease patient previously treat antiHER2 agent 6 . Uncontrolled diarrhea , nausea , vomit 7 . Known malabsorptive disorder 8 . Significant medical disease gastric cancer 9 . Presence neuropathy &gt; Grade 1 ( NCI Common Toxicity Criteria ) 10 . Prior treatment ( include adjuvant therapy ) taxane tubulintargeted agent ( indibulin , eribulin , etc . ) 11 . Prior radiation therapy 25 % bone marrow 12 . Need continue regularlytaken medication potent inhibitor inducer CYP3A pathway 13 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>